Sonoma Pharmaceuticals Valuation
| SNOA Stock | USD 2.79 0.13 4.45% |
Based on Macroaxis valuation methodology, the company appears to be undervalued. Sonoma Pharmaceuticals has a current Real Value of $2.96 per share. The regular price of the company is $2.79. Our model measures the value of Sonoma Pharmaceuticals from inspecting the company fundamentals such as Shares Outstanding of 1.34 M, operating margin of (0.35) %, and Return On Equity of -0.75 as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Sonoma Pharmaceuticals' valuation include:
Price Book 0.6981 | Enterprise Value -97.7 K | Enterprise Value Ebitda (0.17) | Price Sales 0.2942 | Enterprise Value Revenue 0.1412 |
Undervalued
Today
Please note that Sonoma Pharmaceuticals' price fluctuation is dangerous at this time. Calculation of the real value of Sonoma Pharmaceuticals is based on 3 months time horizon. Increasing Sonoma Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Sonoma Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Sonoma Stock. However, Sonoma Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.79 | Real 2.96 | Target 3.25 | Hype 2.8 |
The real value of Sonoma Stock, also known as its intrinsic value, is the underlying worth of Sonoma Pharmaceuticals Company, which is reflected in its stock price. It is based on Sonoma Pharmaceuticals' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Sonoma Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Sonoma Pharmaceuticals helps investors to forecast how Sonoma stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Sonoma Pharmaceuticals more accurately as focusing exclusively on Sonoma Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Sonoma Pharmaceuticals' intrinsic value based on its ongoing forecasts of Sonoma Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Sonoma Pharmaceuticals' closest peers. If more than one evaluation category is relevant for Sonoma Pharmaceuticals we suggest using both methods to arrive at a better estimate.
Sonoma Pharmaceuticals Cash |
|
Sonoma Valuation Trend
Comparing Sonoma Pharmaceuticals' enterprise value against its market capitalization is a good way to estimate the value of Sonoma Pharmaceuticals uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Sonoma Revenue by Product
Sonoma Pharmaceuticals Total Value Analysis
Sonoma Pharmaceuticals is at this time estimated to have valuation of (97.72 K) with market capitalization of 3.74 M, debt of 608 K, and cash on hands of 5.59 M. The negative valuation of Sonoma Pharmaceuticals may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Sonoma Pharmaceuticals fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(97.72 K) | 3.74 M | 608 K | 5.59 M |
Sonoma Pharmaceuticals Investor Information
The company has price-to-book ratio of 0.7. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Sonoma Pharmaceuticals recorded a loss per share of 0.99. The entity last dividend was issued on the 20th of June 2019. The firm had 1:20 split on the 30th of August 2024. Based on the key indicators related to Sonoma Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Sonoma Pharmaceuticals is not in a good financial situation at this time. It has a very high probability of going through financial hardship in January.Sonoma Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Sonoma Pharmaceuticals has an asset utilization ratio of 86.4 percent. This suggests that the Company is making $0.86 for each dollar of assets. An increasing asset utilization means that Sonoma Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Sonoma Pharmaceuticals Ownership Allocation
About 96.09 % of Sonoma Pharmaceuticals outstanding shares are held by general public with 1.5 (%) owned by insiders and only 2.41 % by institutional holders.Sonoma Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 12.73 M. Net Loss for the year was (4.83 M) with profit before overhead, payroll, taxes, and interest of 4.48 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Sonoma Pharmaceuticals' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Sonoma Pharmaceuticals and how it compares across the competition.
About Sonoma Pharmaceuticals Valuation
The stock valuation mechanism determines Sonoma Pharmaceuticals' current worth on a weekly basis. Our valuation model uses a comparative analysis of Sonoma Pharmaceuticals. We calculate exposure to Sonoma Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Sonoma Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 4.7 M | 5.1 M | |
| Pretax Profit Margin | (0.40) | (0.41) | |
| Operating Profit Margin | (0.37) | (0.39) | |
| Net Loss | (0.38) | (0.40) | |
| Gross Profit Margin | 0.37 | 0.25 |
Sonoma Pharmaceuticals Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 454.5 K |
Sonoma Pharmaceuticals Current Valuation Indicators
Valuation refers to the process of determining the present value of Sonoma Pharmaceuticals and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Sonoma we look at many different elements of the entity such as Sonoma's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Sonoma Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Sonoma Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Sonoma Pharmaceuticals' worth.Complementary Tools for Sonoma Stock analysis
When running Sonoma Pharmaceuticals' price analysis, check to measure Sonoma Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sonoma Pharmaceuticals is operating at the current time. Most of Sonoma Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Sonoma Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sonoma Pharmaceuticals' price. Additionally, you may evaluate how the addition of Sonoma Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |